Xenon Provides Corporate Update / Xenon Expands Ion Channel Neurology Pipeline with Addition of XEN496 | Xenon Pharmaceuticals Inc.

Xenon Provides Corporate Update / Xenon Expands Ion Channel Neurology Pipeline with Addition of XEN496

Sep 6, 2018 8:00 AM EDT

Supporting Materials

Xenon Expands Ion Channel Neurology Pipeline with Addition of XEN496, a “Phase 3 Ready” Potassium Channel Modulator for the Treatment of Epilepsy

Investor inquiries

Tucker Kelly
Chief Financial Officer
investors@xenon-pharma.com

Request Information

Email alerts

Sign up here to receive email alerts from Xenon Pharmaceuticals